Literature DB >> 19808657

Insulin-like growth factor-binding protein-5 stimulates growth of human intestinal muscle cells by activation of G{alpha}i3.

Robert S Flynn1, Sunila Mahavadi, Karnam S Murthy, John M Kellum, John F Kuemmerle.   

Abstract

In human intestinal smooth muscle cells, endogenous insulin-like growth factor-I (IGF-I) regulates growth and IGF-binding protein-5 (IGFBP-5) expression. The effects of IGF-I are facilitated by IGFBP-5. We previously showed that IGFBP-5 acts independently of IGF-I in human intestinal muscle to stimulate proliferation and upregulate IGF-I production by activation of Erk1/2 and p38 MAPK. Thus a positive feedback loop exists between IGF-I and IGFBP-5, whereby both stimulate muscle growth and production of the other factor. In Crohn's disease, IGF-I and IGFBP-5 expression are increased and contribute to stricture formation through this effect on muscle growth. To determine the signaling pathways coupling IGFBP-5 to MAPK activation and growth, smooth muscle cells were isolated from muscularis propria of human intestine and placed into primary culture. Erk1/2 and p38 MAPK activation and type I collagen production were measured by immunoblot. Proliferation was measured by [(3)H]thymidine incorporation. Activation of specific G proteins was measured by ELISA. AG1024, an IGF-I receptor tyrosine kinase inhibitor, was used to isolate the IGF-I-independent effects of IGFBP-5. IGFBP-5-induced phosphorylation of Erk1/2 and p38 MAPK and proliferation were abolished by pertussis toxin, implying the participation of Gi. IGFBP-5 specifically activated Gi3 but not other G proteins. Transfection of an inhibitory Galphai minigene specifically inhibited MAPK activation, proliferation, and both collagen-I and IGF-I production. Our results indicate that endogenous IGFBP-5 activates Gi3 and regulates smooth muscle growth, IGF-I production, and collagen production via the alpha-subunit of Gi3, independently of IGF-I, in normal human intestinal muscle cells.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19808657      PMCID: PMC2850095          DOI: 10.1152/ajpgi.00323.2009

Source DB:  PubMed          Journal:  Am J Physiol Gastrointest Liver Physiol        ISSN: 0193-1857            Impact factor:   4.052


  33 in total

1.  Growth inhibition by insulin-like growth factor-binding protein-3 in T47D breast cancer cells requires transforming growth factor-beta (TGF-beta ) and the type II TGF-beta receptor.

Authors:  S Fanayan; S M Firth; A J Butt; R C Baxter
Journal:  J Biol Chem       Date:  2000-12-15       Impact factor: 5.157

Review 2.  Minireview: tissue-specific versus generalized gene targeting of the igf1 and igf1r genes and their roles in insulin-like growth factor physiology.

Authors:  A A Butler; D LeRoith
Journal:  Endocrinology       Date:  2001-05       Impact factor: 4.736

Review 3.  Signalling pathways involved in antiproliferative effects of IGFBP-3: a review.

Authors:  R C Baxter
Journal:  Mol Pathol       Date:  2001-06

4.  Intrinsic actions of IGFBP-3 and IGFBP-5 on Hs578T breast cancer epithelial cells: inhibition or accentuation of attachment and survival is dependent upon the presence of fibronectin.

Authors:  Catherine McCaig; Claire M Perks; Jeff M P Holly
Journal:  J Cell Sci       Date:  2002-11-15       Impact factor: 5.285

5.  Insulin-like growth factor-binding protein-5 (IGFBP-5) stimulates growth and IGF-I secretion in human intestinal smooth muscle by Ras-dependent activation of p38 MAP kinase and Erk1/2 pathways.

Authors:  John F Kuemmerle; Huiping Zhou
Journal:  J Biol Chem       Date:  2002-03-28       Impact factor: 5.157

6.  Coupling of the insulin-like growth factor-I receptor tyrosine kinase to Gi2 in human intestinal smooth muscle: Gbetagamma -dependent mitogen-activated protein kinase activation and growth.

Authors:  J F Kuemmerle; K S Murthy
Journal:  J Biol Chem       Date:  2000-12-18       Impact factor: 5.157

7.  Evidence that IGF binding protein-5 functions as a ligand-independent transcriptional regulator in vascular smooth muscle cells.

Authors:  Qijin Xu; Shenghua Li; Yang Zhao; Travis J Maures; Ping Yin; Cunming Duan
Journal:  Circ Res       Date:  2004-03-04       Impact factor: 17.367

8.  IGF-I elicits growth of human intestinal smooth muscle cells by activation of PI3K, PDK-1, and p70S6 kinase.

Authors:  John F Kuemmerle
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2002-11-20       Impact factor: 4.052

9.  IGFBP-3 activates TGF-beta receptors and directly inhibits growth in human intestinal smooth muscle cells.

Authors:  John F Kuemmerle; Karnam S Murthy; Jennifer G Bowers
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2004-06-03       Impact factor: 4.052

10.  Fibronectin binds insulin-like growth factor-binding protein 5 and abolishes Its ligand-dependent action on cell migration.

Authors:  Qijin Xu; Ben Yan; Shenghua Li; Cunming Duan
Journal:  J Biol Chem       Date:  2003-11-24       Impact factor: 5.157

View more
  11 in total

Review 1.  Insulin-like growth factors in the gastrointestinal tract and liver.

Authors:  John F Kuemmerle
Journal:  Endocrinol Metab Clin North Am       Date:  2012-05-15       Impact factor: 4.741

2.  Amelioration of excess collagen IαI, fibrosis, and smooth muscle growth in TNBS-induced colitis in IGF-I(+/-) mice.

Authors:  Sunila Mahavadi; Robert S Flynn; John R Grider; Li-Ya Qiao; Karnam S Murthy; Krystina B Hazelgrove; John F Kuemmerle
Journal:  Inflamm Bowel Dis       Date:  2010-08-18       Impact factor: 5.325

3.  Increased IGF-IEc expression and mechano-growth factor production in intestinal muscle of fibrostenotic Crohn's disease and smooth muscle hypertrophy.

Authors:  Chao Li; Kent Vu; Krystina Hazelgrove; John F Kuemmerle
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2015-10-01       Impact factor: 4.052

4.  Forkhead box F2 regulation of platelet-derived growth factor and myocardin/serum response factor signaling is essential for intestinal development.

Authors:  Craig Bolte; Xiaomeng Ren; Tatiana Tomley; Vladimir Ustiyan; Arun Pradhan; April Hoggatt; Tanya V Kalin; B Paul Herring; Vladimir V Kalinichenko
Journal:  J Biol Chem       Date:  2015-01-28       Impact factor: 5.157

Review 5.  Recent advances in small bowel diseases: Part II.

Authors:  Alan B R Thomson; Angeli Chopra; Michael Tom Clandinin; Hugh Freeman
Journal:  World J Gastroenterol       Date:  2012-07-14       Impact factor: 5.742

6.  IGFBP5 enhances osteogenic differentiation potential of periodontal ligament stem cells and Wharton's jelly umbilical cord stem cells, via the JNK and MEK/Erk signalling pathways.

Authors:  Yuejun Wang; Zhi Jia; Shu Diao; Xiao Lin; Xiaomeng Lian; Liping Wang; Rui Dong; Dayong Liu; Zhipeng Fan
Journal:  Cell Prolif       Date:  2016-08-03       Impact factor: 6.831

7.  Hyaluronic acid regulates normal intestinal and colonic growth in mice.

Authors:  Terrence E Riehl; Xueping Ee; William F Stenson
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2012-05-03       Impact factor: 4.052

8.  Endogenous IGFBP-3 regulates excess collagen expression in intestinal smooth muscle cells of Crohn's disease strictures.

Authors:  Robert S Flynn; Sunila Mahavadi; Karnam S Murthy; John R Grider; John M Kellum; Homayoon Akbari; John F Kuemmerle
Journal:  Inflamm Bowel Dis       Date:  2011-01       Impact factor: 5.325

9.  Membrane-to-nucleus signaling links insulin-like growth factor-1- and stem cell factor-activated pathways.

Authors:  Yujiro Hayashi; David T Asuzu; Simon J Gibbons; Kirsten H Aarsvold; Michael R Bardsley; Gwen A Lomberk; Angela J Mathison; Michael L Kendrick; K Robert Shen; Takahiro Taguchi; Anu Gupta; Brian P Rubin; Jonathan A Fletcher; Gianrico Farrugia; Raul A Urrutia; Tamas Ordog
Journal:  PLoS One       Date:  2013-10-07       Impact factor: 3.240

10.  Insulin-like growth factor binding proteins increase intracellular calcium levels in two different cell lines.

Authors:  Danielle Seurin; Alain Lombet; Sylvie Babajko; François Godeau; Jean-Marc Ricort
Journal:  PLoS One       Date:  2013-03-19       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.